183 related articles for article (PubMed ID: 14624368)
1. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions.
Metzner KJ; Bonhoeffer S; Fischer M; Karanicolas R; Allers K; Joos B; Weber R; Hirschel B; Kostrikis LG; Günthard HF;
J Infect Dis; 2003 Nov; 188(10):1433-43. PubMed ID: 14624368
[TBL] [Abstract][Full Text] [Related]
2. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
[TBL] [Abstract][Full Text] [Related]
3. Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection.
Arnedo-Valero M; Garcia F; Gil C; Guila T; Fumero E; Castro P; Blanco JL; Miró JM; Pumarola T; Gatell JM
Clin Infect Dis; 2005 Sep; 41(6):883-90. PubMed ID: 16107990
[TBL] [Abstract][Full Text] [Related]
4. Drug resistance mutations during structured treatment interruptions.
Yerly S; Fagard C; Günthard HF; Hirschel B; Perrin L;
Antivir Ther; 2003 Oct; 8(5):411-5. PubMed ID: 14640388
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina.
Vignoles M; Barboni G; Agosti MR; Quarleri J; García MK; Ayala SG; Salomón H
Antivir Ther; 2009; 14(8):1175-81. PubMed ID: 20032547
[TBL] [Abstract][Full Text] [Related]
6. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study.
Ruiz L; Ribera E; Bonjoch A; Romeu J; Martinez-Picado J; Paredes R; Díaz M; Marfil S; Negredo E; García-Prado J; Tural C; Sirera G; Clotet B
J Infect Dis; 2003 Oct; 188(7):977-85. PubMed ID: 14513417
[TBL] [Abstract][Full Text] [Related]
7. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.
Hance AJ; Lemiale V; Izopet J; Lecossier D; Joly V; Massip P; Mammano F; Descamps D; Brun-Vézinet F; Clavel F
J Virol; 2001 Jul; 75(14):6410-7. PubMed ID: 11413308
[TBL] [Abstract][Full Text] [Related]
8. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086.
Benson CA; Vaida F; Havlir DV; Downey GF; Lederman MM; Gulick RM; Glesby MJ; Wantman M; Bixby CJ; Rinehart AR; Snyder S; Wang R; Patel S; Mellors JW;
J Infect Dis; 2006 Nov; 194(9):1309-18. PubMed ID: 17041858
[TBL] [Abstract][Full Text] [Related]
10. Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case.
Torti C; Moretti F; Uccelli MC; Tirelli V; Quiros-Roldan E; Gargiulo F; Carosi G
Med Sci Monit; 2003 Apr; 9(4):CS16-9. PubMed ID: 12709675
[TBL] [Abstract][Full Text] [Related]
11. Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients.
Metzner KJ; Allers K; Rauch P; Harrer T
AIDS; 2007 Mar; 21(6):703-11. PubMed ID: 17413691
[TBL] [Abstract][Full Text] [Related]
12. Genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure.
Montroni M; Monforte AD
Scand J Infect Dis Suppl; 2003; 106():79-81. PubMed ID: 15000591
[TBL] [Abstract][Full Text] [Related]
13. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
[TBL] [Abstract][Full Text] [Related]
14. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
[TBL] [Abstract][Full Text] [Related]
15. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
[TBL] [Abstract][Full Text] [Related]
16. Treatment interruptions in HIV-infected subjects.
Bongiovanni M; Casana M; Tincati C; d'Arminio Monforte A
J Antimicrob Chemother; 2006 Sep; 58(3):502-5. PubMed ID: 16816398
[TBL] [Abstract][Full Text] [Related]
17. Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions.
Foli A; Maserati R; Barasolo G; Castelli F; Tomasoni L; Migliorino M; Maggiolo F; Pan A; Paolucci S; Scudeller L; Tinelli C; D'Aquila R; Lisziewicz J; Lori F
Antivir Ther; 2004 Feb; 9(1):123-32. PubMed ID: 15040544
[TBL] [Abstract][Full Text] [Related]
18. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
[TBL] [Abstract][Full Text] [Related]
19. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.
Campbell TB; Shulman NS; Johnson SC; Zolopa AR; Young RK; Bushman L; Fletcher CV; Lanier ER; Merigan TC; Kuritzkes DR
Clin Infect Dis; 2005 Jul; 41(2):236-42. PubMed ID: 15983922
[TBL] [Abstract][Full Text] [Related]
20. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.
Escoto-Delgadillo M; Vázquez-Valls E; Ramírez-Rodríguez M; Corona-Nakamura A; Amaya-Tapia G; Quintero-Pérez N; Panduro-Cerda A; Torres-Mendoza BM
HIV Med; 2005 Nov; 6(6):403-9. PubMed ID: 16268822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
